undamentalytics Newsletter
Sign in

Seres Therapeutics, Inc. revenue

Seres Therapeutics, Inc.'s revenue was $789,000 in fiscal 2025. Since fiscal 2016 ($21.8m) it has grown at a compound -30.8% a year. Over the last twelve months it was $1.9m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0223228353314570012
Growth on the year before——+47.5%−11.9%+22.1%−3.7%+336.3%−95.1%−100.0%———

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Korsana Biosciences, Inc. $1.9m -12.6% —
Ovid Therapeutics Inc. $1.6m -76.2% 99.8%
Absci Corp $1.6m -62.3% -43.3%
Collplant Biotechnologies Ltd $2.4m 360.4% —
Korro Bio, Inc. $2.4m -62.1% -53.7%

Compare with peers

Head to head: KRSA vs MCRBMCRB vs OVIDABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Seres Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Seres Therapeutics, Inc.